Pericytes and vessel maturation during tumor angiogenesis and metastasis

Authors

  • Ahmad Raza,

    1. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
    Search for more papers by this author
  • Michael J. Franklin,

    1. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
    Search for more papers by this author
  • Arkadiusz Z. Dudek

    Corresponding author
    1. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
    • University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455
    Search for more papers by this author

  • Conflict of interest: Nothing to declare.

Abstract

Despite promising results in preclinical and clinical studies, the therapeutic efficacy of antiangiogenic therapies has been restricted by a narrow focus on inhibiting the growth of endothelial cells. Other cell types in the tumor stroma are also critical to the progression of cancer, including mural cells. Mural cells are vascular support cells that range in phenotype from pericytes to vascular smooth muscle cells. Although the role of pericytes and pericyte-like cells in the pathophysiology of cancer is still unclear, evidence indicates that aberrations in pericyte–endothelial cell signaling networks could contribute to tumor angiogenesis and metastasis. The purpose of this review is to evaluate critically recent evidence on the role of pericytes in tumor biology and discuss potential therapeutic targets for anticancer intervention. Am. J. Hematol. 85:593–598, 2010. © 2010 Wiley-Liss, Inc.

Ancillary